RxDoctor Payments Data

Todd Williams, APRN

Nurse Practitioner · Astoria, ORNPI 1790985463

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,696 of the $4,186 with a category attached, or 88.3%. 21 manufacturers reported payments, led by AbbVie at 27.0% of the total. Among nurse practitioner clinicians in OR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$4,186in general payments, 2019–2025

Across 167 payments — averaging $25.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Johnson & Johnson$725
  • UCB, Inc.$488
  • Sun Pharmaceutical Industries Inc.$373
  • Lilly USA, LLC$361
  • Novartis$351
  • plus $756 from 15 others

What the payments were for

  • Food & beverage$3,69688%
  • Education$49012%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,186 in reported general payments places this provider in the 95th percentile of 997 nurse practitioner providers in Oregon.

See all nurse practitioner providers in Oregon

Medicare billing

Part B allowed, 2024
$474,287
Medicare patients
1,569
Services billed
9,231

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa23$467,363
Dupixent PenDupilumab22$89,779
Tacrolimus38$4,402
Ketoconazole217$4,210
Metronidazole54$2,754
Clobetasol Propionate56$2,661
Betamethasone Dipropionate92$2,596
Triamcinolone Acetonide212$2,554
Doxycycline Hyclate116$1,689
ValacyclovirValacyclovir Hcl36$1,566
Mycophenolate Mofetil14$1,542
Fluorouracil22$1,491
Clindamycin Phosphate34$906
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc55$865
Permethrin21$779

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Teva Pharmaceuticals USA, Inc.Acyclovir$23$16315 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 997 nurse practitioner providers in Oregon.

Other nurse practitioner in Astoria

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →